Evaxion Biotech A/S, a clinical-stage TechBio company focused on developing AI-Immunology™-powered vaccines is pleased to present its novel precision vaccine concept at the 65th Annual Meeting of the American Society of Hematology (ASH), December 9-12, 2023, in San Diego, California.
Selected for Oral Presentation – Evaxion was selected for oral presentation from over 5000 submitted abstracts. The presentation will highlight a breakthrough innovation using the company’s proprietary AI target discovery and development platform, AI-Immunology™. Based on a novel source of target molecules, endogenous retroviruses (ERVs), combined with unique data-driven insights, Evaxion has developed a novel concept for precision vaccines against hematological malignancies and select solid cancers.
Tailored precision vaccines – The precision vaccines are tailored to the specific tumor profiles and immune systems of the respective patient groups. This represents a significant advance in the treatment of complex cancers, including hematologic malignancies. The research results may enable a broader use of vaccines in cancer therapy than previously thought.
Endogenous retroviruses (ERVs) are remnants of ancient viruses that have become part of the human genome. While they remain dormant in normal cells due to tight epigenetic control mechanisms, cancer cells can express these traces, making ERVs ideal targets for cancer vaccines.
Evaxion Biotech A/S is a pioneering TechBio company powered by its proprietary AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decipher the human immune system and develop novel immunotherapies for cancer, bacterial diseases and viral infections. Based on AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline with novel personalized vaccines and a preclinical infectious disease pipeline with bacterial and viral diseases with high unmet medical needs. Evaxion’s mission is to improve patients’ lives through innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI Immunology™ platform and vaccine pipeline.
SOURCE: GlobeNewswire
